Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leukotriene modifiers.

Teal S Hallstrand1, William R Henderson

  • 1Division of Pulmonary and Critical Medicine, University of Washington, Box 356522, 1959 NE Pacific Street, Seattle, WA 98195-6588, USA. tealh@u.washington.edu

The Medical Clinics of North America
|November 14, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: Insights into the specific factors that influence the association between DHEA-S levels and asthma.

Annals of the American Thoracic Society·2026
Same author

Viral replication and interferon responses in bronchial epithelia is enhanced by Th17 cells.

American journal of respiratory cell and molecular biology·2026
Same author

Human Rhinovirus A16 Infection of Mast Cells Promotes T2 and Non-T2 Immune Responses That Are Modulated by the Airway Epithelium.

Allergy·2026
Same author

Secreted phospholipase A2 group X regulates peripheral sensitization to allergen.

JCI insight·2026
Same author

IL-13 Modulates Antiviral Effector and Proinflammatory Pathways in Rhinovirus-Infected Pediatric Bronchial Epithelium.

bioRxiv : the preprint server for biology·2025
Same author

Viral replication and interferon responses in bronchial epithelia is enhanced by Th17 cells.

bioRxiv : the preprint server for biology·2025
Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026
Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026
Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026
Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026
Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026
Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026
See all related articles

Leukotriene modifiers effectively treat asthma by improving lung function and reducing exacerbations. These treatments offer significant benefits with minimal adverse effects for various asthma types.

Area of Science:

  • Biochemistry
  • Pulmonology
  • Pharmacology

Background:

  • Leukotrienes (LTs) are key mediators in asthma pathogenesis.
  • LTs influence vascular permeability, mucus production, and smooth muscle constriction.
  • LTs may contribute to airway remodeling in asthma.

Purpose of the Study:

  • To evaluate the efficacy of leukotriene modifiers in asthma management.
  • To assess the role of LT modifiers in different asthma severities and specific conditions.

Main Methods:

  • Review of evidence on leukotriene modifiers in asthma treatment.
  • Analysis of LT modifier effects on airflow limitation, quality of life, and exacerbations.
  • Comparison of LT modifiers with standard therapies.

Related Experiment Videos

Main Results:

  • LT modifiers improve airflow and quality of life in mild-to-moderate asthma.
  • Combination therapy with LT modifiers and inhaled corticosteroids enhances lung function in moderate-to-severe asthma.
  • LT modifiers are effective for exercise-induced and aspirin-induced bronchoconstriction.

Conclusions:

  • Leukotriene modifiers are valuable therapeutic agents for asthma.
  • These agents demonstrate a favorable safety profile with few adverse effects.
  • LT modifiers offer significant benefits across a spectrum of asthma presentations.